Pharmaceutical Industry

Drug Development Drug Pricing Drug Manufacturing Market Trends Market Competition Drug Manufacturers Market Dynamics Manufacturing Pricing Strategies Novo Nordisk

FDA Approves First Oral GLP-1 for Obesity as Novo’s Wegovy Pill Sets January U.S. Launch

The pill debuts with a $149 introductory cash price for the starter dose under a White House arrangement.

FDA Approves Aqvesme for Thalassemia Anemia, First U.S. Therapy for Both Patient Groups

CMS Unveils Voluntary BALANCE Program to Lower GLP-1 Costs for Medicare and Medicaid

FDA Approves Novo Nordisk’s Wegovy Pill, First Oral GLP-1

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

FDA Approves Wegovy Weight-Loss Pill as First Oral GLP-1 for Obesity

FDA Grants Accelerated Approval to Subcutaneous Lunsumio for Relapsed Follicular Lymphoma

AstraZeneca Withdraws Andexxa From U.S. Market After FDA Says Risks Outweigh Benefits

White House Adds 9 Pharma Deals, Extending Drug-Price Pacts to 14 Manufacturers

White House Secures Nine More Drugmaker Pacts on MFN Pricing as TrumpRx Nears Launch

Trump Adds Nine Pharma Giants to Drug Pricing Deals, Reaching 14 Signatories as TrumpRx Nears Launch

Medicare’s First Negotiated Drug Prices Take Effect Jan. 1, Cutting 2026 Costs

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies

Lilly Files Orforglipron Obesity Pill With FDA After Trial Shows Weight-Loss Maintenance

Trump Poised to Launch Medicare CBD Pilot as Early as 2026

FDA Adds Brain Tumor Warning to Two Depo‑Provera Injections

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

FDA Clears GSK’s Exdensur as First Twice-Yearly Add-On for Severe Eosinophilic Asthma

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer